RxDoctor Payments Data

Luis Pineda, MD

Hematology-Oncology · Vestavia, ALNPI 1538125695

Payments from drug & device makers

$3,509in general payments, 2019–2025

Across 197 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$390
  • Johnson & Johnson$310
  • AstraZeneca$218
  • Incyte Corporation$213
  • Bristol Myers Squibb$203
  • Pfizer$198
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$3,27893%
  • Education$2317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few hematology-oncology providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$42,293
Medicare patients
65
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate13$325,951
JakafiRuxolitinib Phosphate18$313,410
Lenalidomide11$162,570
Somatuline DepotLanreotide Acetate13$88,232
EliquisApixaban67$50,978
XareltoRivaroxaban61$46,208
ProcritEpoetin Alfa19$19,992
Xtampza ErOxycodone Myristate12$14,709
OxycontinOxycodone Hcl13$12,101
Esomeprazole Magnesium21$3,071
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen123$2,893
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen46$2,523
Nebivolol Hcl16$2,474
Fentanyl23$2,159
Omeprazole43$1,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$56$325,95113 claims
Incyte CorporationJakafi$213$313,41018 claims
Johnson & JohnsonXarelto, Procrit$310$66,20080 claims
PfizerEliquis$198$50,97867 claims
Collegium Pharmaceutical, Inc.Xtampza Er$81$14,70912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other hematology-oncology in Vestavia

Where these figures come from

Is this you, or does something look wrong? →